Drug labeling must reflect origin of active ingredient -- U.S. Customs NAFTA rule.
DRUG LABELING MUST REFLECT BULK PHARMACEUTICAL COUNTRY OF ORIGIN under a recent Customs Service decision, the Washington, D.C. law firm McKenna & Cuneo warns manufacturers in a June 28 client advisory. "Drug manufacturers and distributors of pharmaceutical products made with imported active ingredients should re-examine their country-of- origin labeling as a result of a position statement of the U.S. Customs Service" issued June 6 to implement the North American Free Trade Agreement, McKenna & Cuneo states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth